S
Stephen J. Tomlanovich
Researcher at University of California, San Francisco
Publications - 47
Citations - 3078
Stephen J. Tomlanovich is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 30, co-authored 47 publications receiving 2963 citations. Previous affiliations of Stephen J. Tomlanovich include University of San Francisco.
Papers
More filters
Journal ArticleDOI
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine.
TL;DR: The increase in cyclosporine bioavailability observed in this study is most likely explained by inhibition of gastrointestinal cytochrome P450 enzymes, and is unlikely that ketoconazole had a significant effect on either cyclospora absorption or hepatic blood flow.
Journal ArticleDOI
Prednisone withdrawal, in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study
Nasimul Ahsan,Donald E. Hricik,Arthur J. Matas,Stephen Rose,Stephen J. Tomlanovich,Alan H. Wilkinson,Marian Ewell,Matthew McIntosh,Donald Stablein,Ernest E. Hodge,Daniel H. Hayes,Paul F. Gores,David M. Cohen,Thomas A. Gonwa,Karl Brinler,Robert C. Harland,John F. Neylan,Mark D. Pescovitz,James J. Wynn,Harold C-Yang,William M. Bennett,John B. Copley,John Dunn,S. Tomlanovich,Lawrence Chan,J. Andrew Bertolatus,Mathew R. Weir,Robert Mendez,John D. Pirsch,J. Harold Helderman +29 more
TL;DR: For recipients on cyclosporine/mycophenolate mofetil/P with no AR at 90 days, the chance of developing subsequent AR is small; if P is tapered and withdrawn, the risk increases, but the majority remain free of acute and chronic rejection.
Journal ArticleDOI
Recurrent focal glomerulosclerosis: Natural history and response to therapy
TL;DR: The efficacy of these modalities supports the notion that recurrent FGS is caused by a circulating humoral mediator and may best be obtained with a combination of treatment modalities including cyclosporine, ACE inhibitors, and early use of plasmapheresis.
Journal ArticleDOI
Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.
Peter G. Stock,Michelle E. Roland,Laurie Carlson,Chris E. Freise,John P. Roberts,Ryutaro Hirose,Norah A. Terrault,Lynda A. Frassetto,Joel M. Palefsky,Stephen J. Tomlanovich,Nancy L. Ascher +10 more
TL;DR: Preliminary data are encouraging and indicate that transplantation should be a treatment option for individuals with well-controlled HIV disease, as is the possible poor outcome in hepatitis C virus-coinfected liver transplant recipients.
Journal ArticleDOI
The role of donor-specific HLA alloantibodies in liver transplantation.
Jacqueline G. O'Leary,Anthony J. Demetris,Lawrence S. Friedman,Howard Gebel,Philip F. Halloran,Allan D. Kirk,Stuart J. Knechtle,S. V. McDiarmid,Abraham Shaked,Paul I. Terasaki,Kathryn Tinckam,Stephen J. Tomlanovich,Kathryn J. Wood,E. S. Woodle,Andrea A. Zachary,Goran B. Klintmalm +15 more
TL;DR: Standardized DSA testing and diagnostic criteria for both acute and chronic AMR are needed to distil existing associations into etiological processes in order to develop responsive therapeutic strategies.